Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

. The lesion is bright red and commonly referred to as a "strawberry mark".

Local complications may occur in the form of ulceration and critical localisations such as the eye area or the upper respiratory tract. These complications are the serious forms of the disease and represent 10% of total haemangioma occurrence, or 1% of births. First intention treatment is usually long-term systemic corticotherapy. The trouble with this kind of treatment is that it involves numerous and sometimes serious side-effects that are well known in infants.

About Pierre Fabre:

Pierre Fabre Laboratories, France's second biggest independent pharmaceutical laboratory, achieved a turnover of 1.75 billion euros in 2008. It employs nearly 10,000 people including 1,400 in the research sector. Its business sectors are ethical drugs, healthcare products and dermocosmetics with the brands Avene, Ducray/A Derma, Galenic/Elancyl, Klorane and Rene Furterer. Pierre Fabre Dermatologie, as part of Pierre Fabre Dermocosmetique, is specialised in prescription drugs.

In 2008, Pierre Fabre Medicament dedicated 33% of its annual turnover to R&D in five main therapeutic areas: oncology (priority sector with 50% of the overall R&D budget), Central Nervous System, cardiology, internal medicine/urology and dermatology. To find out more about Pierre Fabre Laboratories: http://www.pierre-fabre.com


'/>"/>
SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Therapies to Address the Underlying Cause of Cystic,Fibrosis; ... SOUTH PLAINFIELD, N.J., Aug. 20 New ... that the investigational oral drug,PTC124 demonstrates activity in ... with PTC124 results in statistically significant,improvements in the ...
... Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY) announced today that ... on August 14, 2008 indicating that Oncothyreon does ... The NASDAQ Global Market,because it does not meet ... (i) the market value of Oncothyreon,s common stock ...
... Crystal Research Associates, LLC,announced today that ... on Generex Biotechnology Corporation (Nasdaq: GNBT ... at http://www.crystalra.com ., Generex Biotechnology ... pharmaceutical company that aims to research, develop, ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3
(Date:4/22/2014)... of Yale researchers will lead a five-year, $3 million ... events is affecting the transport of dissolved organic matter ... say could alter the chemical composition and water quality ... funding from the National Science Foundation,s MacroSystems Biology program, ... the watershed, which begins in Canada and runs through ...
(Date:4/22/2014)... fist-like club of a mantis shrimp, a team of ... with University of Southern California and Purdue University, have ... more impact resistant and tougher than the standard used ... of this tiny crustacean, the more we realize its ... day," said David Kisailus, a Kavli Fellow of the ...
(Date:4/22/2014)... The Federation of American Societies for Experimental Biology (FASEB) ... (FY) 2013 highlighting how funding from the National Institutes ... DC, and Puerto Rico. "FASEB is pleased to make ... the significance of NIH to their state," said FASEB ... nation,s leading source for biomedical research funding, investing ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... of children with undiagnosed learning disorders, developmental deficits, and ... challenges, which are explored in detail in a reflective ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... ahead of print at www.liebertpub.com/gtmb ...
... been extinct for 65 million years, newly published data ... is providing invaluable insights into their paleobiology. Ammonites, shelled ... inhabited the oceans for nearly 350 million years. Specimens ... that covered North America during the Cretaceous Period demonstrate ...
... are investigating a potential new treatment for lung disease that ... is studying how statins, drugs which are commonly used to ... , There is currently no effective treatment for acute ... rates for those who become critically ill and suffer lung ...
Cached Biology News:Unexplained childhood disorders 2New discoveries in North America's Great Plains bring ammonites to life 2New discoveries in North America's Great Plains bring ammonites to life 3Queen's University Belfast lung injury study could save lives in critically ill 2